AI Consensus Investment Thesis
Intuitive Surgical (ISRG) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Buy & Hold
Multiple horizons support ownership with measured follow-through.
1-Year
BUY$449
+12.0%5-Year
BUY$726
+80.9%Latest flagship insight
Why This High-Multiple Medical Technology Giant Faces A Hidden Valuation Gravity
There is high consensus that this medical robotics leader possesses an exceptional recurring revenue model and a pristine balance sheet. However, sharp divergence exists regarding near-term valuation multiple compression under restrictive monetary policy, as high interest rates threaten hospital capital budgets and pharmaceutical innovations pressure bariatric procedure volumes.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The core investment thesis centers on a classic value-ownership dilemma: a fundamentally exceptional business trading at an extreme valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry that leaves no margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry. While the rollout of the next-generation platform and a highly resilient razor-and-blade recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry model will drive robust mid-teens earnings expansion, these gains are likely to be diluted by multiple contraction in a sticky-rate, capital-constrained macro regimemacro regimeA persistent combination of growth, inflation, policy, and liquidity conditions affecting asset prices.View full glossary entry. Professional quants must balance near-term multiple gravity against long-term AI-data compounding.
Key insights
- The recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry engine, comprising approximately eighty percent of sales, provides a highly visible and durable cash flow floor.
- The next-generation platform rollout initiates a multi-year upgrade cycle, deepening hospital switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and surgeon lock-in.
- A pristine, zero-debt balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry insulates the firm from credit-market stress and provides immense capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry optionality.
- Valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression acts as a heavy anchor, as a fifty-times multiple faces mechanical gravity under restrictive rates.
- GLP-1 adoptionglp 1 adoptionThe rate at which GLP-1-based therapies are prescribed, accessed, and used by eligible patients.View full glossary entry presents a structural, partially unpriced headwind to bariatric procedure volumes, though offset by multi-platform expansion.
- The proprietary kinesthetic telemetry dataset establishes an insurmountable moat, transitioning the long-term narrative toward physical AI infrastructureai infrastructureThe compute, networking, storage, power, cooling, software, and facilities used to develop and operate AI systems.View full glossary entry.
- Tactical capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry, including aggressive share repurchases, establishes a structural valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry during periods of macro-driven volatility.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The mainstream market narrative views the asset as an infallible, untouchable healthcare monopoly that is entirely immune to macroeconomic gravity. The crowd assumes that the rollout of the next-generation robotic system will drive years of frictionless upgrades, perpetual double-digit revenue growth, and immediate margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry. Retail and sell-side analysts systematically ignore valuation risks, treating the stock as a mandatory safe-haven holding. Concurrently, some media narratives harbor exaggerated anxieties that emerging weight-loss drugs will completely eradicate bariatric surgery volumes, while others fear that late-arriving competitors will trigger an immediate price warprice warIntense competitive price cutting that can reduce industry margins and alter market share.View full glossary entry and commoditize robotic hardware.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's mischaracterization of the business model and its valuation arithmetic. While the crowd analyzes the firm as a cyclical hardware manufacturer vulnerable to hospital capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry budgets, it is actually an unregulated utility and applied AI platform. Approximately eighty percent of revenue is recurring consumable spend tied directly to inelastic procedure volumes, which insulates cash flows from macro freezes. Furthermore, the market misprices the immense option value of the proprietary kinesthetic telemetry dataset, which forms an unreproducible training ground for autonomous surgery. Conversely, the crowd ignores the near-term multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry risk under a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry, expecting flawless execution to sustain an elevated multiple when mathematical gravity dictates a valuation resetvaluation resetA material adjustment in price or valuation multiples after expectations or required returns change.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence catalyst will be a bifurcated event. First, consecutive quarterly earnings prints will demonstrate that procedure volumes and recurring instrument revenues are accelerating despite a constrained hospital capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry environment, proving the inelasticity of the business model. Second, the explicit breakout and monetization of high-margin software and AI-analytics subscriptions, such as case insights, will force the market to capitulate. Analysts will be forced to re-rate the asset from a cyclical medical device multiple to an enterprise AI platform multiple within the next eighteen to twenty-four months.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment assessments exhibit a clear split. Some views highlight extreme optimism surrounding the next-generation upgrade cycle and AI data monetization, placing the asset in an overshoot phase. Conversely, other perspectives focus on multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry risks and hospital capital constraints, categorizing the sentiment as fearful or stabilizing. This divergence stems from whether analysts prioritize near-term valuation gravityvaluation gravityAn informal expression for the tendency of price to move toward levels supported by earnings, cash flow, or historical valuation norms.View full glossary entry or long-term structural compoundingstructural compoundingLong-term growth in earnings, cash flow, or intrinsic value supported by durable reinvestment opportunities or recurring advantages.View full glossary entry.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of sticky inflation, elevated interest rates, and tight liquidity presents a mixed setup. It acts as a structural headwind for the asset's elevated valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry, applying mechanical downward pressure on long-duration growth equities. However, it serves as a powerful tailwind for the underlying business. Chronic hospital labor shortages and rising operational costs make the platform's efficiency and labor-productivity gains highly non-discretionary. Additionally, the company's pristine, zero-debt balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry entirely insulates it from credit-market stress, allowing it to thrive while leveraged competitors struggle.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreements across the reports center on the severity of near-term multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and the velocity of the next-generation upgrade cycle. Some perspectives assume that hospital capital constraints and high interest rates will severely delay system placements, forcing a painful multiple contraction toward historical averages. Other views argue that the platform's labor-saving efficiency makes it non-discretionary, allowing the upgrade cycle to defy macro headwindsmacro headwindsBroad economic conditions that can slow growth, weaken demand, or pressure asset valuations.View full glossary entry. Additionally, there is minor disagreement regarding the long-term threat of pharmaceutical weight-loss drugs on overall procedure volumes, with some modeling permanent structural demand destructiondemand destructionA reduction in demand caused by prices, scarcity, substitution, policy, or weaker economic conditions.View full glossary entry and others viewing it as a temporary narrative overhang.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Razor-and-Blade Recurring Revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry Engine | Operational Efficiency | +40% | +45% | Approximately eighty percent of total revenue is derived from recurring instruments, accessories, and services. Once a system is installed, it forces a perpetual annuity of high-margin consumable sales. This recurring engine isolates cash flows from cyclical hospital capital-expenditure droughts, ensuring highly visible and durable free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry compounding that protects earnings through broader macroeconomic contractions. |
| Da Vinci 5 Upgrade Cycle | Innovation And Product | +25% | +30% | The rollout of the next-generation platform initiates a massive, multi-year replacement cycle across the global installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry. Featuring a ten-thousand-fold increase in computing power, force-feedback instrumentation, and integrated AI analytics, the platform raises switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and surgeon lock-in, securing long-term hospital capital commitments and preserving immense pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. |
| Proprietary Kinesthetic Telemetry Moat | Competitive Positioning | +20% | +15% | The company possesses the largest repository of digitized human surgical motion in existence. By harvesting millions of surgical video records and kinematic data, the firm trains machine learning models that competitors cannot replicate. This network centralitynetwork centralityHow important a node is in a network based on how strongly it connects and influences flows across the system.View full glossary entry transitions the hardware into an intelligent copilot, establishing an insurmountable moat against low-cost hardware copycats. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry and Capital Allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry | Capital Allocation | +15% | +10% | Operating with a debt-to-equity ratio of practically zero and billions in cash, the company is completely immune to refinancing riskrefinancing riskThe danger that a company cannot replace maturing debt obligations with new financing under favorable terms.View full glossary entry or credit spread blowouts. This financial sovereignty allows management to self-fund aggressive research and development, execute multi-billion-dollar counter-cyclical share repurchases, and effortlessly acquire distressed technology startups while heavily indebted peers struggle. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation Multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry Compression | Macroeconomic And Macrofinancial | -25% | -0.0% | Trading at a trailing price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry above fifty in a sticky interest rate environment defies basic financial physics. High discount rates mathematically compress the valuation premium of long-duration growth assets. This extreme valuation leaves zero margin for execution error, acting as a mechanical gravitational drag on absolute price appreciation. |
| Hospital Capital Expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry Constriction | Macroeconomic And Macrofinancial | -12% | -10% | Stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry, labor inflation, and elevated energy costs compress hospital operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. While recurring consumable revenue is protected, the deployment of new, multi-million-dollar systems relies on hospital capital budgets. Extended sales cycles and delayed fleet upgrades temporarily compress top-line velocity and introduce cyclical volatility. |
| GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry Induced TAMtotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry Reduction | Sector And Industry | -10% | -8.0% | The rapid advancement and broader adoption of highly efficacious oral GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry weight-loss therapeutics permanently impair the total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry for bariatric surgeries. While bariatrics represent a minority of total procedure volume, the narrative overhang and the actual loss of high-growth incremental procedures act as a measurable friction on overall volume growth. |
| Emerging Robotic Competition and Pricing Pressure | Competitive Positioning | -8.0% | -6.0% | Well-capitalized competitors are methodically advancing through clinical and regulatory pathways. While switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry are immense, the mere presence of viable alternatives breaks the absolute pricing monopoly, allowing hospital procurement departments to leverage multi-vendor negotiations to squeeze hardware pricing and force elevated research and development spending. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Catastrophic Cyber or AI Malfunction | 15% | -35% | Operational Efficiency | A critical software failure, cybersecurity breach, or artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry hallucination during a live procedure results in severe patient outcomes. This would prompt immediate regulatory suspensions, stalling the next-generation rollout, destroying the brand trust moat, and exposing the firm to catastrophic litigation and multi-billion-dollar repricing. |
| Antitrust Right-to-Repair Intervention | 15% | -30% | Regulatory | Regulators successfully appeal antitrust dismissals, legally mandating interoperability with third-party, low-cost generic instrument manufacturers. This would instantly destroy the closed-ecosystem razor-and-blades model, collapsing gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry from their historical high levels to hardware-commodity levels and forcing a violent downward re-rating of the stock. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Level-3 Autonomous Surgical Clearance | 25% | +35% | Innovation And Product | The regulatory authority clears fully autonomous surgical sub-routines for specific high-volume, low-complexity tasks without real-time human intervention. This transitions the platform from a mechanical tool to a labor-replacement artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry entity, expanding the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry exponentially as surgical throughput becomes decoupled from human surgeon fatigue limits. |
| Bio-Data and Software SaaSsoftware as a serviceA software delivery model in which customers access hosted applications, commonly through recurring subscriptions or usage-based charges.View full glossary entry Monetization | 35% | +20% | Innovation And Product | The company successfully launches a high-margin software-as-a-service subscription tier to monetize its multi-petabyte library of surgical telemetry. By allowing pharmaceutical and biotech firms to train on spatial outcomes, the firm creates a high-margin software revenue stream entirely divorced from hardware manufacturing, justifying a software-tier valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry. |
Company Financial Analysis
Intuitive Surgical Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The financial reports paint a picture of a highly profitable business operating at peak performance. Recent annual revenues have surged past ten billion dollars, growing at over twenty percent year-over-year, while net margins remain exceptionally strong at around twenty-eight percent. The assessments strongly agree that the company's financial engine is incredibly healthy, driven by a highly reliable stream of recurring revenue from surgical supplies. However, there is a clear clash regarding how this growth will translate to stock performance. Some views warn that because the stock is currently priced so high, future stock returns will lag behind the company's actual business growth due to inevitable valuation adjustments. Others remain highly confident that the sheer force of cash flow compounding and aggressive share buybacks will easily overcome these valuation hurdles, making it a safe-haven asset for long-term investors.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 10.1B | USD 2.9B | USD 2.5B |
| 2024 | USD 8.4B | USD 2.3B | USD 1.3B |
| 2023 | USD 7.1B | USD 1.8B | USD 749.6M |
| 2022 | USD 6.2B | USD 1.3B | USD 958.4M |
| 2021 | USD 5.7B | USD 1.7B | USD 1.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 71.5x | TTM | Native | USD / USD |
| 2024 | 81.8x | TTM | Native | USD / USD |
| 2023 | 67.2x | TTM | Native | USD / USD |
| 2022 | 71.6x | Annual | Native | USD / USD |
| 2021 | 77.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company maintains exceptionally high and stable profit margins, with gross margins locked near sixty-seven percent and operating margins hovering around twenty-nine percent. This incredible profitability is driven by the company's highly successful business model, where hospitals must continuously purchase proprietary, high-margin instruments for every surgery performed. The reports agree that these margins reflect immense pricing power and a deeply entrenched customer base. However, opinions clash regarding the future direction of these margins. Some views suggest that operating margins will expand further toward thirty-five percent as high-margin software and artificial intelligence subscriptions are introduced. Conversely, other assessments caution that rising raw material costs, global supply chain disruptions, and the arrival of cheaper competitor systems could put downward pressure on margins, making the stock's expensive valuation multiple highly sensitive to any potential profit slips.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 2.9B | 29.3% | 28.4% |
| 2024 | USD 2.3B | 28.1% | 27.8% |
| 2023 | USD 1.8B | 24.8% | 25.2% |
| 2022 | USD 1.6B | 25.3% | 21.3% |
| 2021 | USD 1.8B | 31.9% | 29.9% |
Balance sheet and leverage
The company's balance sheet is described as an impenetrable financial fortress, boasting over twenty billion dollars in total assets and virtually zero debt. The reports are in absolute agreement that this debt-free structure makes the company completely safe from rising interest rates, credit tightening, and refinancing risks. In a difficult economic climate where heavily indebted competitors are struggling to survive, this financial safety acts as a powerful shield. Furthermore, it provides management with immense flexibility to play offense. The company can easily fund its own research, offer flexible leasing terms to cash-strapped hospitals, and execute massive multi-billion-dollar share buybacks to support the stock price. There are no major disagreements on this front; the company's financial safety and firepower are considered world-class, offering investors ultimate peace of mind.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 302.8M | USD 5.9B | USD 3.1B net cash | 4.87x |
| 2024 | USD 146M | USD 4B | USD 1.9B net cash | 4.07x |
| 2023 | USD 89.8M | USD 5.2B | USD 2.8B net cash | 4.76x |
| 2022 | USD 93.8M | USD 4.1B | USD 1.6B net cash | 4.40x |
| 2021 | USD 87M | USD 4.2B | USD 1.2B net cash | 5.08x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates with a highly efficient, capital-light business model that is a massive advantage in today's high-interest-rate environment. Traditional spending on physical buildings and equipment is very low, hovering around five percent of revenue, as hospitals bear the primary cost of installing the machines. Instead, the company heavily concentrates its spending on research and development, investing over one billion dollars annually to fund next-generation platforms and advanced software. The reports agree that this disciplined spending generates spectacular returns on invested capital and keeps the company far ahead of its rivals. While some analysts suggest monitoring potential short-term costs related to manufacturing rollouts, the consensus is clear: the company's ability to self-fund its technological future without borrowing expensive money makes it an incredibly strong and safe investment for the long haul.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 539.8M | USD 1.3B |
| 2024 | USD 1.1B | USD 1.1B |
| 2023 | USD 1.1B | USD 998.8M |
| 2022 | USD 532.4M | USD 879M |
| 2021 | USD 353.5M | USD 671M |
Quarterly Forecast Scenarios
Intuitive Surgical Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $391.93 | $423.17 | $447.31 | $736.09 | |
| $372.33 | $433.12 | $474.15 | $724.14 | |
| $357.44 | $436.12 | $479.16 | $713.57 | |
| $371.74 | $449.38 | $487.05 | $723.38 | |
| $390.32 | $453.65 | $488.36 | $716.61 | |
| $404.35 | $472.53 | $517.66 | $738.34 | |
| $420.53 | $482.63 | $528.16 | $746.91 | |
| $428.94 | $503.58 | $544.94 | $771.93 | |
| $420.36 | $513.82 | $561.29 | $782.73 | |
| $441.38 | $530.60 | $588.29 | $807.31 | |
| $454.62 | $544.36 | $605.93 | $822.72 | |
| $450.07 | $560.66 | $628.37 | $846.10 | |
| $468.08 | $573.32 | $630.21 | $852.53 | |
| $482.12 | $599.89 | $655.42 | $882.91 | |
| $472.48 | $614.51 | $678.39 | $900.46 | |
| $481.93 | $626.71 | $723.73 | $922.67 | |
| $496.38 | $651.26 | $747.86 | $935.91 | |
| $516.24 | $683.94 | $807.69 | $952.30 | |
| $511.08 | $699.67 | $831.92 | $976.28 | |
| $526.41 | $725.92 | $865.19 | $1,002 |
Research Provenance
References & Context
This Intuitive Surgical consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).